Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Apogee Therapeutics Inc (APGE)

Apogee Therapeutics Inc (APGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,266,105
  • Shares Outstanding, K 68,320
  • Annual Sales, $ 0 K
  • Annual Income, $ -182,150 K
  • EBIT $ -283 M
  • EBITDA $ -295 M
  • 60-Month Beta 1.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.74

Options Overview Details

View History
  • Implied Volatility 58.30% (+0.13%)
  • Historical Volatility 47.49%
  • IV Percentile 11%
  • IV Rank 4.70%
  • IV High 236.20% on 06/20/25
  • IV Low 49.53% on 12/10/25
  • Expected Move (DTE 6) 3.01 (3.90%)
  • Put/Call Vol Ratio 11.40
  • Today's Volume 310
  • Volume Avg (30-Day) 115
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 7,664
  • Open Int (30-Day) 8,202
  • Expected Range 74.07 to 80.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.05
  • Number of Estimates 4
  • High Estimate -0.99
  • Low Estimate -1.16
  • Prior Year -1.19
  • Growth Rate Est. (year over year) +11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.15 +26.05%
on 11/14/25
78.11 -1.32%
on 12/12/25
+13.98 (+22.16%)
since 11/12/25
3-Month
35.39 +117.80%
on 09/22/25
78.11 -1.32%
on 12/12/25
+40.20 (+109.00%)
since 09/12/25
52-Week
26.20 +194.20%
on 04/08/25
78.11 -1.32%
on 12/12/25
+32.76 (+73.92%)
since 12/12/24

Most Recent Stories

More News
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated...

APGE : 77.08 (+0.72%)
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential...

APGE : 77.08 (+0.72%)
Apogee Therapeutics to Participate in Upcoming Conferences

SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences....

APGE : 77.08 (+0.72%)
Apogee Therapeutics Raises $323.3 Million in Offering

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Apogee Therapeutics...

APGE : 77.08 (+0.72%)
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class...

APGE : 77.08 (+0.72%)
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class...

APGE : 77.08 (+0.72%)
Canaccord Genuity Sticks to Their Buy Rating for Apogee Therapeutics (APGE)

In a report released today, Edward Nash from Canaccord Genuity maintained a Buy rating on Apogee Therapeutics, with a price target of $89.00. The company’s shares closed yesterday at $39.61.Elevate Your...

APGE : 77.08 (+0.72%)
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for...

APGE : 77.08 (+0.72%)
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

SAN FRANCISCO and BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Stifel 2025...

APGE : 77.08 (+0.72%)
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX...

APGE : 77.08 (+0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Apogee Therapeutics LLC is a biotechnology company advancing novel, potentially therapies to address the needs of the millions of people living with immunological and inflammatory disorders. Apogee Therapeutics LLC is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 82.27
2nd Resistance Point 80.19
1st Resistance Point 78.64
Last Price 77.08
1st Support Level 75.00
2nd Support Level 72.92
3rd Support Level 71.37

See More

52-Week High 78.11
Last Price 77.08
Fibonacci 61.8% 58.28
Fibonacci 50% 52.16
Fibonacci 38.2% 46.03
52-Week Low 26.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar